Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Recruiting now

Conditions studied: Atopic Dermatitis

In brief

The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

Key facts

Study ID

NCT06988605

Run by

Galderma R&D

People needed

1000

Starts

2025-07-14

Expected to finish

2027-11-30

Last updated by the study team

2026-03-13

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®).
• Adolescent and adult participants aged >=12 years with moderate-to-severe AD.
• Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.

You may not qualify if…

• Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label.
• Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline.
• Participants who received nemolizumab previously.
• Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.

Where it is running

• Galderma Investigational Site 7071 — Caledonia, Michigan, United States (enrolling)
• Galderma Investigational Site # 7052 — East Syracuse, New York, United States (enrolling)
• Galderma Investigational Site 8012 — Glenn Dale, Maryland, United States (enrolling)
• Galderma Investigationa Site 7104 — Milford, Massachusetts, United States (enrolling)
• Galderma Investigational Site 8848 — Las Vegas, Nevada, United States (enrolling)
• Galderma Investigational Site - Site 7080 — Auburn, New York, United States (enrolling)
• Galderma Investigational Site 8142 — Indianapolis, Indiana, United States (enrolling)
• Galderma Investigational Site 7098 — Columbia, Maryland, United States (enrolling)
• Galderma Investigational Site 7068 — Rockville, Maryland, United States (enrolling)
• Galderma Investigational Site 7065 — Brighton, Massachusetts, United States (enrolling)
• Galderma Investigational Site 7060 — Phoenix, Arizona, United States (enrolling)
• Galderma Investigational Site 7057 — Lee's Summit, Missouri, United States (enrolling)
• Galderma Investigational Site 7059 — Fairfield, Connecticut, United States (enrolling)
• Galderma Investigational Site 7055 — Portsmouth, New Hampshire, United States (enrolling)
• Galderma Investigational Site 8224 — Fremont, California, United States (enrolling)
• Galderma Investigational Site 7063 — Cutler Bay, Florida, United States (enrolling)
• Galderma Investigational Site 7134 — Hollywood, Florida, United States (enrolling)
• Galderma Investigational Site - 8535 — Phoenix, Arizona, United States (enrolling)
• Galderma Investigational Site 7078 — Miami, Florida, United States (enrolling)
• Galderma Investigational Site 8553 — Newport Beach, California, United States (enrolling)
• Galdrma Investigational Site - 7077 — Phoenix, Arizona, United States (enrolling)
• Galderma Investigational Site 7090 — St. Petersburg, Florida, United States (enrolling)
• Galderma Investigational Site 7054 — Tampa, Florida, United States (enrolling)
• Galderma Investigational Site 7058 — Chicago, Illinois, United States (enrolling)
• Galderma Investigational Site - 7051 — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.